Le Lézard
Classified in: Health, Science and technology, Business
Subject: AWD

Optum360® Recognized by Frost & Sullivan for Leadership Position in Revenue Cycle Management Coding and Clinical Documentation Improvement


SANTA CLARA, Calif., Dec. 7, 2017 /PRNewswire/ -- Based on its recent analysis of the revenue cycle management (RCM) coding and clinical documentation market, Frost & Sullivan recognizes Optum360, a leader in revenue management solutions for health care providers, with its 2017 U.S. Market Leadership Award. The award recognizes proven leadership by Optum360 for Optum® Enterprise CAC and Optum® CDI 3D solutions, powered by its proprietary natural language processing (NLP) technology.

2017 United States RCM Coding and Clinical Documentation Market Leadership Award

The U.S. healthcare industry is in need of revenue cycle solutions that support healthcare organizations in the transition to various reimbursement models. Prevalent financial solutions often fail to effectively capture appropriate reimbursement from health plans for a wide variety of patient services commonly rendered by hospitals and physician practices. Many services are related to complex chronic conditions and associated complications that require advanced clinical documentation and coding.

"The transition from ICD-9 to ICD-10 codes helped care providers realize that their underlying health information management (HIM) encoders were not adequately equipped to manage the increased coding specificities of ICD-10, which includes 28 times as many procedure codes and 5 times as many diagnosis codes. ICD-10, payer-specific coding requirements, and higher scrutiny for coding compliance are driving care providers to opt for more efficient coding products that primarily include CDI and CAC solutions," said Koustav Chatterjee, Industry Analyst - Digital Health.

Optum360 has developed technologically advanced products that foster seamless interoperability between CDI and coding departments. Powered by Optum NLP, these solutions help improve revenue cycle performance and can:

"The driving force of Optum Enterprise CAC and Optum CDI 3D is the unique capability of the company's patented NLP, which helps customers accelerate clinical documentation improvement and accurate code assignment, contributing to revenue integrity and operational efficiency. Optum360 consultants, trainers, IT implementers and performance management experts ensure that every care provider can achieve measurable results and receive support throughout the engagement to manage the transition toward accountable financial management," said Chatterjee.

"Optum360 enables our clients to achieve better financial and operational performance in support of their mission to deliver quality care for their patients and communities," said Optum360 CEO Tom Boehning. "We are grateful to receive this award from Frost & Sullivan and to be recognized as the industry leader for CAC and CDI innovation."

Frost & Sullivan's independent market analysis confirms Optum360 as the proven market leader in the important RCM IT segment of CAC and CDI. The Optum360 corporate culture of innovation promotes continual product improvements and fortifies the company's visionary technological capabilities. Patented technologies, coupled with an experienced support staff, ensure that customers thrive with better financial outcomes. For its strong overall performance in the RCM coding and clinical documentation market, Optum360 has earned the 2017 U.S. Market Leadership Award.

Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product, which in turn raise customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Optum360
Optum360 simplifies the business of health care by delivering health information, services and technology to hospitals, physicians and health systems. Our 7,700 performance experts provide revenue cycle leadership, innovation and operational excellence to eliminate the inefficiencies in health care and prepare for value-based reimbursement. By creating solutions that leverage our resources, relationships and unparalleled industry perspective, we partner with care providers to fulfill their strategic vision and enable them to focus on care and healing.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Claudia Toscano
P: 210.477.8417
F: 210.348.1003
E: [email protected]

 

SOURCE Frost & Sullivan


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: